GlassScriptPhysician profile
Rosenberg A Reyes
NPI 1861465254
$17,531.54
in general payments reported to CMS, 2019-2025
57 companies · $2,584 in 2025
The $2,584 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $1,890 · 2021: $3,662 · 2022: $2,496 · 2023: $3,170 · 2024: $2,758 · 2025: $2,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,366 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,366.20 |
| Education | $145.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,957.59 | 2021-2025 | |
| Novo Nordisk INC | $1,853.02 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,790.44 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $1,302.38 | 2021-2025 | |
| Pfizer INC. | $1,012.75 | 2019-2025 | |
| Lilly USA, LLC | $939.21 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merz North America, INC. | $797.50 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $774.10 | 2019-2025 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $681.56 | 2019-2024 | |
| Lundbeck LLC | $601.87 | 2022-2025 | Rexulti |
| Esperion Therapeutics, INC. | $562.75 | 2020-2025 | Nexletol |
| Allergan, INC. | $489.83 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $480.36 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $469.60 | 2020-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $435.25 | 2020-2025 | Trintellix |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosenberg Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.